Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe SepsisSteven M. Opal, for the ACCESS Study Group, Mark Tidswell et al.|JAMA|2013Cited by 797
Phase 2 trial of eritoran tetrasodium (E5564), a Toll-like receptor 4 antagonist, in patients with severe sepsis*Mark Tidswell, Steven M. Opal, Janice L. Wheeler et al.|Critical Care Medicine|2009Cited by 226
Influence of Severity of Illness on the Effects of Eritoran Tetrasodium (E5564) and on Other Therapies for Severe SepsisAndré C. Kalil, Steven M. Opal, Melvyn Lynn et al.|Shock|2011Cited by 35
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe SepsisSteven M. Opal, Daniel P. Rossignol, Derek C. Angus et al.|Unknown|2013Cited by 7